A randomized, crossover, phase I clinical study to evaluate bioequivalence and safety of tofacitinib and Xeljanz® in Chinese healthy subjects.
Xu Z, Wang Y, Liu Z, Zhang R, Zhou Y, Yu J, Lan J, Liang W, Liu G, Qu X, Chen J, Su Z, Yu S, Cheng Y, Wang W, Ren Q, Deng Q, Zhao Y, Yang H.
Xu Z, et al.
Int Immunopharmacol. 2022 Aug;109:108780. doi: 10.1016/j.intimp.2022.108780. Epub 2022 Apr 20.
Int Immunopharmacol. 2022.
PMID: 35461158
Clinical Trial.